Development and in vitro evaluation of core-shell type lipid-polymer hybrid nanoparticles for the delivery of erlotinib in non-small cell lung cancer

European Journal of Pharmaceutical Sciences

Volumn 81, Issue , 2016, Pages 162-171

  Mandal, Bivash ^a   Mittal, Nivesh K ^a   Balabathula, Pavan ^a   Thoma, Laura A ^a   Wood, George C ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Core?shell; Drug delivery; Erlotinib; Lipid polymer hybrid nanoparticles; Non small cell lung cancer

Indexed keywords

ERLOTINIB; LIPID; NANOSHELL; PHOSPHATIDYLCHOLINE; POLYCAPROLACTONE; POLYMER; 1,2-DISTEAROYL-SN-GLYCERO-3-PHOSPHOETHANOLAMINE-N-METHOXY-POLY(ETHYLENE GLYCOL 2000); ANTINEOPLASTIC AGENT; MACROGOL DERIVATIVE; NANOPARTICLE; PHOSPHATIDYLETHANOLAMINE; POLYESTER; PROTEIN KINASE INHIBITOR;

A549 CELL LINE; ARTICLE; CELL VIABILITY ASSAY; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG RELEASE; DRUG SCREENING; DRUG STABILITY; DRUG STORAGE; HUMAN; HUMAN CELL; HYBRID; IN VITRO STUDY; INFRARED SPECTROMETRY; LIPID MONOLAYER; NON SMALL CELL LUNG CANCER; PARTICLE SIZE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; ZETA POTENTIAL; CARCINOMA, NON-SMALL-CELL LUNG; CELL SURVIVAL; CHEMISTRY; DRUG EFFECTS; LUNG NEOPLASMS; TRANSMISSION ELECTRON MICROSCOPY; TRANSPORT AT THE CELLULAR LEVEL; TUMOR CELL LINE; TUMOR STEM CELL ASSAY; ULTRASTRUCTURE;

ANTINEOPLASTIC AGENTS; BIOLOGICAL TRANSPORT; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL SURVIVAL; DRUG DELIVERY SYSTEMS; DRUG LIBERATION; ERLOTINIB HYDROCHLORIDE; HUMANS; LUNG NEOPLASMS; MICROSCOPY, ELECTRON, TRANSMISSION; NANOPARTICLES; PHOSPHATIDYLCHOLINES; PHOSPHATIDYLETHANOLAMINES; POLYESTERS; POLYETHYLENE GLYCOLS; PROTEIN KINASE INHIBITORS; TUMOR STEM CELL ASSAY;

EID: 84945941529     PISSN: 09280987     EISSN: 18790720     Source Type: Journal    
DOI: 10.1016/j.ejps.2015.10.021     Document Type: Article

References (54)

1. A. Bershteyn, M.C. Hanson, M.P. Crespo, J.J. Moon, A.V. Li, H. Suh, and D.J. Irvine Robust IgG responses to nanograms of antigen using a biomimetic lipid-coated particle vaccine J. Control. Release 157 2012 354 365
2. H.J. Bovenschen, and J.A. Alkemade Erlotinib-induced dermatologic side-effects Int. J. Dermatol. 48 2009 326 328
3. V.D. Cataldo, D.L. Gibbons, R. Perez-Soler, and A. Quintas-Cardama Treatment of non-small-cell lung cancer with erlotinib or gefitinib N. Engl. J. Med. 364 2011 947 955
4. W.K. Chang, Y.J. Tai, C.H. Chiang, C.S. Hu, P.D. Hong, and M.K. Yeh The comparison of protein-entrapped liposomes and lipoparticles: preparation, characterization, and efficacy of cellular uptake Int. J. Nanomedicine 6 2011 2403
5. J.S. Chawla, and M.M. Amiji Biodegradable poly(epsilon-caprolactone) nanoparticles for tumor-targeted delivery of tamoxifen Int. J. Pharm. 249 2002 127 138
6. W.S. Cheow, and K. Hadinoto Factors affecting drug encapsulation and stability of lipid-polymer hybrid nanoparticles Colloids Surf. B: Biointerfaces 85 2011 214 220
7. M.E. Davis Nanoparticle therapeutics: an emerging treatment modality for cancer Nat. Rev. Drug Discov. 7 2008 771 782
8. R.H. Fang, S. Aryal, C.M. Hu, and L. Zhang Quick synthesis of lipid-polymer hybrid nanoparticles with low polydispersity using a single-step sonication method Langmuir 26 2010 16958 16962
9. N.A. Franken, H.M. Rodermond, J. Stap, J. Haveman, and C. van Bree Clonogenic assay of cells in vitro Nat. Protoc. 1 2006 2315 2319
10. K. Fu, D.W. Pack, A.M. Klibanov, and R. Langer Visual evidence of acidic environment within degrading poly(lactic-co-glycolic acid) (PLGA) microspheres Pharm. Res. 17 2000 100 106
11. E. Herzog, A. Casey, F.M. Lyng, G. Chambers, H.J. Byrne, and M. Davoren A new approach to the toxicity testing of carbon-based nanomaterials - the clonogenic assay Toxicol. Lett. 174 2007 49 60
12. M. Houchin, and E. Topp Chemical degradation of peptides and proteins in PLGA: a review of reactions and mechanisms J. Pharm. Sci. 97 2008 2395 2404
13. C.M. Hu, and L. Zhang Nanoparticle-based combination therapy toward overcoming drug resistance in cancer Biochem. Pharmacol. 83 2012 1104 1111
14. M.L. Immordino, F. Dosio, and L. Cattel Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential Int. J. Nanomedicine 1 2006 297 315
15. T. Ito, L. Sun, M.A. Bevan, and R.M. Crooks Comparison of nanoparticle size and electrophoretic mobility measurements using a carbon-nanotube-based coulter counter, dynamic light scattering, transmission electron microscopy, and phase analysis light scattering Langmuir 20 2004 6940 6945
16. B. Kong, J.H. Seog, L.M. Graham, and S.B. Lee Experimental considerations on the cytotoxicity of nanoparticles Nanomedicine (London) 6 2011 929 941
17. I. Kritikou, E. Giannopoulou, A.K. Koutras, V.T. Labropoulou, and H.P. Kalofonos The Combination of Antitumor Drugs, Exemestane and Erlotinib, Induced Resistance Mechanism in H358 and A549 Non-small Cell Lung Cancer (NSCLC) Cell Lines 2013 (Epub)
18. A. Kroll, M.H. Pillukat, D. Hahn, and J. Schnekenburger Interference of engineered nanoparticles with in vitro toxicity assays Arch. Toxicol. 86 2012 1123 1136
19. A.T. Lam, J. Yoon, E.O. Ganbold, D.K. Singh, D. Kim, K.H. Cho, S.J. Son, J. Choo, S.Y. Lee, S. Kim, and S.W. Joo Adsorption and desorption of tyrosine kinase inhibitor Erlotinib on gold nanoparticles J. Colloid Interface Sci. 425 2014 96 101
20. X.Q. Liu, and T.K. Qiao Radiosensitizing effect of Erlotinib on human lung adenocarcinoma cell line A549 Zhonghua Zhong Liu Za Zhi 35 2013 819 823
21. Y. Ma, Y. Zheng, X. Zeng, L. Jiang, H. Chen, R. Liu, L. Huang, and L. Mei Novel docetaxel-loaded nanoparticles based on PCL-Tween 80 copolymer for cancer treatment Int. J. Nanomedicine 6 2011 2679 2688
22. R.M. Mainardes, M.P.D. Gremião, and R.C. Evangelista Thermoanalytical study of praziquantel-loaded PLGA nanoparticles Rev. Bras. Ciên Farm. 42 2006 523 530
23. B. Mandal, H. Bhattacharjee, N. Mittal, H. Sah, P. Balabathula, L.A. Thoma, and G.C. Wood Core-shell-type lipid-polymer hybrid nanoparticles as a drug delivery platform Nanomed. Nanotechnol. Biol. Med. 9 2013 474 491
24. G. Marslin, C.J. Sheeba, V.K. Kalaichelvan, R. Manavalan, P.N. Reddy, and G. Franklin Poly(d,l-lactic-co-glycolic acid) nanoencapsulation reduces Erlotinib-induced subacute toxicity in rat J. Biomed. Nanotechnol. 5 2009 464 471
25. V.A.d. Mello, and E. Ricci-Júnior Encapsulation of naproxen in nanostructured system: structural characterization and in vitro release studies Quim. Nova 34 2011 933 939
26. J. Mendelsohn, and J. Baselga The EGF receptor family as targets for cancer therapy Oncogene 19 2000 6550 6565
27. O. Mir, B. Blanchet, and F. Goldwasser More on aprepitant for Erlotinib-induced pruritus N. Engl. J. Med. 364 2011 487
28. S. Moghimi, and J. Szebeni Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties Prog. Lipid Res. 42 2003 463 478
29. J.R. Molina, P. Yang, S.D. Cassivi, S.E. Schild, and A.A. Adjei Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship Mayo Clin. Proc. 83 2008 584 594
30. S.W. Morton, M.J. Lee, Z.J. Deng, E.C. Dreaden, E. Siouve, K.E. Shopsowitz, N.J. Shah, M.B. Yaffe, and P.T. Hammond A nanoparticle-based combination chemotherapy delivery system for enhanced tumor killing by dynamic rewiring of signaling pathways Sci. Signal. 7 2014 ra44
31. S.K. Pal, R.A. Figlin, and K. Reckamp Targeted therapies for non-small cell lung cancer: an evolving landscape Mol. Cancer Ther. 9 2010 1931 1944
32. W. Peng, X.-y. Jiang, Y. Zhu, E. Omari-Siaw, W.-w. Deng, J.-n. Yu, X.-m. Xu, and W.-m. Zhang Oral delivery of capsaicin using MPEG-PCL nanoparticles Acta Pharmacol. Sin. 36 2015 139 148
33. R.A. Petros, and J.M. DeSimone Strategies in the design of nanoparticles for therapeutic applications Nat. Rev. Drug Discov. 9 2010 615 627
34. R.D. Petty, L.A. Sutherland, E.M. Hunter, and I.A. Cree Comparison of MTT and ATP-based assays for the measurement of viable cell number J. Biolumin. Chemilumin. 10 1995 29 34
35. M. Provencio, D. Isla, A. Sánchez, and B. Cantos Inoperable stage III non-small cell lung cancer: current treatment and role of vinorelbine J. Thorac. Dis. 3 2011 197 204
36. M. Ranson, H. Shaw, J. Wolf, M. Hamilton, S. McCarthy, E. Dean, A. Reid, and I. Judson A phase I dose-escalation and bioavailability study of oral and intravenous formulations of Erlotinib (Tarceva, OSI-774) in patients with advanced solid tumors of epithelial origin Cancer Chemother. Pharmacol. 66 2010 53 58
37. C. Salvador-Morales, L. Zhang, R. Langer, and O.C. Farokhzad Immunocompatibility properties of lipid-polymer hybrid nanoparticles with heterogeneous surface functional groups Biomaterials 30 2009 2231 2240
38. M. Sardan, M. Kilinc, R. Genc, A.B. Tekinay, and M.O. Guler Cell penetrating peptide amphiphile integrated liposomal systems for enhanced delivery of anticancer drugs to tumor cells Faraday Discuss. 166 2013 269 283
39. F.A. Shepherd, J. Rodrigues Pereira, T. Ciuleanu, E.H. Tan, V. Hirsh, S. Thongprasert, D. Campos, S. Maoleekoonpiroj, M. Smylie, R. Martins, M. van Kooten, M. Dediu, B. Findrug loadingay, D. Tu, D. Johnston, A. Bezjak, G. Clark, P. Santabarbara, L. Seymour, and National Cancer Institute of Canada Clinical Trials, G. Erlotinib in previously treated non-small-cell lung cancer N. Engl. J. Med. 353 2005 123 132
40. K. Shien, H. Yamamoto, J. Soh, S. Miyoshi, and S. Toyooka Drug resistance to EGFR tyrosine kinase inhibitors for non-small cell lung cancer Acta Med. Okayama 68 2014 191 200
41. R. Siegel, J. Ma, Z. Zou, and A. Jemal Cancer statistics, 2014 CA Cancer J. Clin. 64 2014 9 29
42. J.N. Spaans, and G.D. Goss Drug resistance to molecular targeted therapy and its consequences for treatment decisions in non-small-cell lung cancer Front Oncol. 4 2014 190
43. J. Thevenot, A. Troutier, L. David, T. Delair, and C. Ladavière Steric stabilization of lipid/polymer particle assemblies by poly (ethylene glycol)-lipids Biomacromolecules 8 2007 3651 3660
44. A. Troutier, T. Delair, C. Pichot, and C. Ladavière Physicochemical and interfacial investigation of lipid/polymer particle assemblies Langmuir 21 2005 1305 1313
45. A.-L. Troutier, L. Véron, T. Delair, C. Pichot, and C. Ladavière New insights into self-organization of a model lipid mixture and quantification of its adsorption on spherical polymer particles Langmuir 21 2005 9901 9910
46. A.L. Troutier-Thuilliez, J. Thevenot, T. Delair, and C. Ladavière Adsorption of plasmid DNA onto lipid/polymer particle assemblies Soft Matter 5 2009 4739 4747
47. S. Vrignaud, J. Hureaux, S. Wack, J.-P. Benoit, and P. Saulnier Design, optimization and in vitro evaluation of reverse micelle-loaded lipid nanocarriers containing Erlotinib hydrochloride Int. J. Pharm. 436 2012 194 200
48. T. Wang, R.A. Nelson, A. Bogardus, and F.W. Grannis Jr. Five-year lung cancer survival: which advanced stage nonsmall cell lung cancer patients attain long-term survival? Cancer 116 2010 1518 1525
49. Westheim, R., 2008. Crystalline Erlotinib. US Patent 11/829482.
50. H. Wong, A. Rauth, R. Bendayan, J. Manias, M. Ramaswamy, Z. Liu, S. Erhan, and X. Wu A new polymer-lipid hybrid nanoparticle system increases cytotoxicity of doxorubicin against multidrug-resistant human breast cancer cells Pharm. Res. 23 2006 1574 1585
51. Y. Yang, W.S. Cheow, and K. Hadinoto Dry powder inhaler formulation of lipid-polymer hybrid nanoparticles via electrostatically-driven nanoparticle assembly onto microscale carrier particles Int. J. Pharm. 434 2012 49 58
52. Z. Yang, X. Luo, X. Zhang, J. Liu, and Q. Jiang Targeted delivery of 10-hydroxycamptothecin to human breast cancers by cyclic RGD-modified lipid-polymer hybrid nanoparticles Biomed. Mater. 8 2013 025012
53. L. Zhang, J.M. Chan, F.X. Gu, J.W. Rhee, A.Z. Wang, A.F. Radovic-Moreno, F. Alexis, R. Langer, and O.C. Farokhzad Self-assembled lipid-polymer hybrid nanoparticles: a robust drug delivery platform ACS Nano 2 2008 1696 1702
54. Y. Zhao, D. Lin, F. Wu, L. Guo, G. He, L. Ouyang, X. Song, W. Huang, and X. Li Discovery and in vivo evaluation of novel RGD-modified lipid-polymer hybrid nanoparticles for targeted drug delivery Int. J. Mol. Sci. 15 2014 17565 17576